The review, "Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies” was published in the journal “Frontiers in Immunology” by ITU faculty member Prof. Dr. Ayça Sayı Yazgan and Res. Assis. Zeynep Nur Şentürk.


Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer, known for its high mortality rate and unfavorable prognosis. One of the primary reasons for the ineffectiveness of current treatments lies in the immunosuppressive nature of the PDAC tumor microenvironment (TME). Regulatory B cells (Bregs) dispersed within the TME have been shown to dampen anti-tumor immune responses. Bregs achieve this by secreting anti-inflammatory cytokines such as IL-10 and IL-35, which promote tumor growth and metastasis. The investigation of Bregs' role in the PDAC microenvironment has gained attention as it holds promise for developing innovative immunotherapeutic approaches. Prof. Dr. Ayça Sayı Yazgan’s research group published a mini-review to aims to illuminate the emerging significance of B cells in PDAC development and progression, with a particular focus on regulatory B cells (Bregs). Furthermore, they explore the potential association of Bregs with immunotherapies in PDAC. By shedding light on these current findings, the review aims to enhance our understanding of the unlimited potential of B cells in the realm of immunotherapy. This review was published by the prestigious international journal Frontiers in Immunology (a Q1 journal in the field of Immunology according to the Scopus index) and unraveled the intricate interplay between B cells and the PDAC microenvironment. This newfound knowledge may pave the way for the development of more effective immunotherapies that exploit the full potential of B cells in combating PDAC and improving patient outcomes.